Belite Bio

About Belite Bio

Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as atrophic age-related macular degeneration (AMD), also known as Geographic Atrophy (GA), and autosomal recessive Stargardt disease (STGD1). Their mission is to treat the untreatable by developing therapies for blindness, liver disease, and diabetes.

Products & Services

Tinlarebant (LBS-008):A novel oral therapy aimed at reducing toxin accumulation in the eye causing Stargardt Disease (STGD1) and contributing to Geographic Atrophy (GA) in Dry AMD. Currently in Phase 3 trials for both GA (Phoenix trial) and STGD1 (Dragon trial), and Phase 2/3 trial (Dragon II) for STGD1. It has received multiple designations including Orphan Drug, Rare Pediatric Disease, Breakthrough Therapy, Fast Track in the US, and Sakigake in Japan.

LBS-009:A therapy targeting metabolic diseases such as Non-Fatty Liver Disease and Type 2 Diabetes. Currently in the preclinical stage.

Specialties

Retinal Degenerative Eye Diseases Therapeutics for Blindness Therapies for Liver Disease Therapies for Diabetes RBP4 (Retinol Binding Protein 4) Intellectual Property

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 350000000 MR: - FA: 350.0 million FAN: 350000000	D: 2025-12-01 FD: 2025-12-01	7 investors
2	RT: PIPE T: - FT: PIPE	A: 125000000 MR: - FA: approximately $125 million FAN: 125000000	D: 2025-09-08 FD: 2025-09-08	6 investors
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 15000000 MR: - FA: $15 million FAN: 15000000	D: 2025-08-07 FD: 2025-08-07	1 investors
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 15000000 MR: - FA: approximately $15 million FAN: 15000000	D: 2025-02-05 FD: 2025-02-05	1 investors
5	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 28750000 MR: - FA: US$28.75 million FAN: 28750000	D: 2024-11-03 FD: 2024-11-03	-
6	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 25000000 MR: - FA: 25 million FAN: 25000000	D: 2024-04-25 FD: 2024-04-25	1 investors
7	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 30000000 MR: - FA: $30 million FAN: 30000000	D: 2023-05-30 FD: 2023-05-30	3 investors

Public Offering Latest

2025-12-01

$350.0M

7 investors (Pro only)

PIPE 2025-09-08

$125.0M

Registered Direct Offering 2025-08-07

$15.0M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Tom Lin

Chairman & CEO

H

Hendrik Scholl

Chief Medical Officer

N

Nathan L. Mata

Chief Scientific Officer

H

Hao-Yuan Chuang

CFO & Director

H

Hung-Wei Chen

Director

W

Wan-Shan Chen

Director

View 6 more team members with Pro

Unlock Full Team Directory

Recent News

Belite Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised